pembrolizumab


( Last Updated : June 6, 2022)
Generic Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Melanoma Adjuvant Treatment
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0286-000
Call for patient/clinician input closed:
Tumour Type:
Skin & Melanoma
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Skin & Melanoma
Indications:
Pembrolizumab is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open28-Mar-22
Call for patient/clinician input closed20-May-22
Clarification:

- Patient input submission received from Melanoma Canada and Save Your Skin Foundation

Submission received26-Apr-22
Submission accepted
Review initiated11-May-22
Draft CADTH review report(s) provided to sponsor for comment26-Jul-22
Deadline for sponsors comments05-Aug-22
CADTH review report(s) and responses to comments provided to sponsor01-Sep-22
Expert committee meeting (initial)14-Sep-22
Draft recommendation issued to sponsorSeptember 26, 2022
To
September 28, 2022
Draft recommendation posted for stakeholder feedback06-Oct-22
End of feedback period21-Oct-22